rare disease and access to innovation
2025 · 4th Quarter (Oct 1 - Dec 31)
AMYLYX PHARMACEUTICALS
Filed by TARPLIN, DOWNS & YOUNG, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 21, 2026
- Income
- $40,000.00
- Expenses
- Not reported
- Registrant
- TARPLIN, DOWNS & YOUNG, LLC
- Client
- AMYLYX PHARMACEUTICALS
- Filing UUID
- 9974ebdc-8963-4e6b-b162-04579dfd192b
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
rare disease and access to innovation
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.